SGMT Stock Forecast & Price Target

Sagimet Biosciences is poised for potential success with their FASN inhibitors, especially denifanstat, as it enters Phase 3 trials and is expected to drive growth in the second half of 2021. Though there may be risks, such as potential competition and financial concerns, the drug has a strong chance of approval and a clear path to market, making it a positive investment opportunity. With the potential for significant impact in the acne market and a low regulatory risk, Sagimet Biosciences has the potential for long-term success and growth.

Sagimet Biosciences is still in the clinical stage of development and faces significant challenges in securing financing and obtaining FDA approval for their novel FASN inhibitors. Although their drug candidate denifanstat may have a competitive edge in the acne treatment market, there is no guarantee of success and the projected peak sales of $2.2B by 2037 seem overly optimistic. Furthermore, as a biopharmaceutical company with a single business segment, they are heavily reliant on the success of this one drug and face added risks if it fails to gain market approval.